GeneFerm Biotechnology Co Ltd (1796) — Cash Flow Reinvestment Rate
GeneFerm Biotechnology Co Ltd (1796) has a Cash Flow Reinvestment Rate of 8.19x as of June 2025, reinvesting NT$11.86 Million (capex NT$5.98 Million plus investments NT$-5.88 Million) from operating cash flow of NT$1.45 Million. See GeneFerm Biotechnology Co Ltd (1796) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GeneFerm Biotechnology Co Ltd Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for GeneFerm Biotechnology Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see how efficiently does GeneFerm Biotechnology Co Ltd generate cash.
Annual Cash Flow Reinvestment Rate for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year capital reinvestment analysis for GeneFerm Biotechnology Co Ltd. See GeneFerm Biotechnology Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 5.63x | NT$45.53 Million | NT$8.09 Million | NT$22.70 Million | ▲ +654.1% |
| 2023 | 0.75x | NT$142.02 Million | NT$190.31 Million | NT$71.40 Million | ▼ -83.6% |
| 2022 | 4.56x | NT$558.75 Million | NT$122.43 Million | NT$278.42 Million | ▲ +76.1% |
| 2021 | 2.59x | NT$290.86 Million | NT$112.23 Million | NT$145.61 Million | ▼ -11.0% |
| 2020 | 2.91x | NT$164.36 Million | NT$56.42 Million | NT$82.32 Million | ▼ -60.9% |
| 2019 | 7.45x | NT$109.43 Million | NT$14.69 Million | NT$54.57 Million | ▲ +437.6% |
| 2018 | 1.39x | NT$58.39 Million | NT$42.14 Million | NT$28.81 Million | ▼ -24.0% |
| 2017 | 1.82x | NT$111.31 Million | NT$61.08 Million | NT$55.16 Million | — |